Navigation Links
Treating Knee Ligament Injuries
Date:3/2/2009

Identifying level of injury is key to treating MCLs nonsurgically, study finds

ROSEMONT, Ill., March 2 /PRNewswire-USNewswire/ -- Injuries to the knee's medial cruciate ligament (MCL) may be treated successfully without surgery, according to a literature review published in the March 2009 issue of The Journal of the American Academy of Orthopaedic Surgeons (JAAOS). The key, the review's authors found, is properly diagnosing and understanding the extent of the injury to determine the best course of treatment.

The MCL is the most frequently injured ligament in the knee. It attaches to the femur (thigh bone) and the tibia (shin bone) and runs across the inside of the knee. MCL injuries are usually caused by a direct blow to the knee, very common in contact sports such as football, rugby or soccer.

Injuries to the MCL may be isolated, or they may be part of a more complex injury involving the anterior cruciate ligament (ACL), posterior cruciate ligament (PCL) or meniscus (cartilage between the bones in the knee joint). Knowing whether other structures in the knee are involved is vital to treating these injuries.

"In most cases, MCL injuries can be treated non-operatively, with a combination of rehabilitation and bracing," says Ryan G. Miyamoto, M.D., sports medicine fellow at the Steadman-Hawkins Clinic in Vail, Colorado. "Surgery becomes an option when there are multiple injuries present in the knee. However, the additional injuries are not always identified."

Thorough physical examinations and appropriate imaging are of paramount importance in managing MCL injuries, say the study authors. In addition, they add that high-grade MCL injuries are often associated with other ligament injuries, so orthopaedic surgeons should pay particular attention to the other joint structures in those cases.

Non-surgical treatment of MCL injuries generally consists of:

  • Early rehabilitation with range of motion and strengthening exercises, along with use of a hinged knee brace.
  • Anti-inflammatory medications and low-intensity ultrasound are also being used with some success.
  • Other nonsurgical treatments, such as gene therapy, growth factors, and small intestine submucosa, which is a naturally derived biomaterial isolated from the small intestine of pigs.

All are currently in their early stages of use, but may hold some promise.

Surgical treatment of MCL injuries may include primary repair or reconstruction of the ligament(s), depending on the stability of the knee. Rehabilitation and bracing is required following surgery.

"We need to be very critical of the stability of the knee, which can be a factor in how well the knee heals and whether it is reinjured," Miyamoto says. "Injuries like these are best overseen by an orthopaedic surgeon."

saveyourknees.org

JAAOS

AAOS

Orthoinfo.org

Knee ligament injuries

Disclosure: The authors did not receive any outside funding or grants in support of their research for or preparation of this work. Neither they nor a member of their immediate families received payments or other benefits or a commitment or agreement to provide such benefits from a commercial entity. No commercial entity paid or directed, or agreed to pay or direct, any benefits to any research fund, foundation, division, center, clinical practice, or other charitable or nonprofit organization with which the authors, or a member of their immediate families, are affiliated or associated.


'/>"/>
SOURCE American Academy of Orthopaedic Surgeons
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
2. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
3. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
4. First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting
5. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
6. Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids
7. NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy
8. Pivotal Phase III Data Confirm the Efficacy and Safety of Arpidas Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
9. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
10. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
11. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... , February 9, 2016 ... announced a collaboration with 10x Genomics to develop ... single-cell biology and bioinformatics. --> QGEN ... collaboration with 10x Genomics to develop and promote ... and bioinformatics. --> QIAGEN N.V. (NASDAQ: ...
(Date:2/9/2016)... 9, 2016 Mast Therapeutics, Inc. (NYSE ... sickle cell disease and heart failure, today announced that it ... purchase common stock in an underwritten public offering.  The offering ... be no assurance as to whether or when the offering ... terms of the offering.   --> ...
(Date:2/9/2016)... FRANCISCO , February 9, 2016 ... biotechnology company focused on developing products for Regenerative Medicine, ... be a featured presenting company at Source Capital Group,s ... on February 10-11, 2016 in New York ... on Wednesday, February 10, 2016 at 12:30 pm by ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit ... as the latest addition to its growing list of Partner Firms. S.S. ... Southeast, from Orlando to Huntsville and in between. , Harnessing the experience and ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: ... winner and inspirational speaker Jan Fox will serve as keynote speaker at the ... provide participants with tools to more effectively communicate with their own organizational staff ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... it has been awarded the prestigious Distinguished Emerald Club of the World award, ... by BoardRoom magazine, one of the most respected trade publications serving private clubs. ...
(Date:2/10/2016)... Petaluma, CA (PRWEB) , ... February 10, 2016 , ... ... newest and most versatile series of monitor mounts ever. , “Our goal was ... flexible and easy to install system that we have ever created.” said Darren Hulsey, ...
(Date:2/10/2016)... ... February 09, 2016 , ... A new leadership team for Mid-South ... President Joe Wiley made the announcement Monday night, Feb. 8, prior to the evening ... of FHU and the creator of GO! Camp, has been named director. Gayle McDonald, ...
Breaking Medicine News(10 mins):